Journal Club

2016


Viral an host responses after stopping long-term nocleos(t)ide analogue therapy in HbeAg-negative chronic hepatitis B

19.12.2016 (Lisa Brockhaus)
C.Höner: Viral an host responses after stopping long-term nocleos(t)ide analogue therapy in HbeAg-negative chronic hepatitis B JID 2016:214 1492-7 2016

Antifungal therapy for patients with proven or suspected Candida peritonitis: Amarcand2, a prospective cohort study in French intensive care units

12.12.2016 (Fabian Franzeck)
Montravers P.: Antifungal therapy for patients with proven or suspected Candida peritonitis: Amarcand2, a prospective cohort study in French intensive care units CMI In Press 2016

Using preexposure prophylaxis, losing condoms? Preexposure prophylaxis promotion may undermine safe sex

05.12.2016 (Marcel Stöckle)
Alaei K. et al.: Using preexposure prophylaxis, losing condoms? Preexposure prophylaxis promotion may undermine safe sex AIDS 30 2753-6 2016

Adjunctive Azithromycin Prophylaxis for Cesarean Delivery

21.11.2016 (Richard Kühl)
Tita et al.: Adjunctive Azithromycin Prophylaxis for Cesarean Delivery NEJM 375 1231-41 2016

Partial restoration of the microbiota of cesarean-born infants via vaginal microbial transfer

14.11.2016 (Vladimira Hinic)
Dominguez-Bello et al.: Partial restoration of the microbiota of cesarean-born infants via vaginal microbial transfer Nat Med. 22(3) 250-3 2016

Empirical Micafungin Treatment and Survival Without Fungal Infection in Adults with ICU-Acquired Sepsis, Candida Colonization, and Multiple Organ Failure. The EMPIRICUS Randomized Clinical Trial

07.11.2016 (Michael Osthoff)
Timsit JF et al.: Empirical Micafungin Treatment and Survival Without Fungal Infection in Adults with ICU-Acquired Sepsis, Candida Colonization, and Multiple Organ Failure. The EMPIRICUS Randomized Clinical Trial JAMA Oct 18;316(15) 1555-1564 2016

Human commensals producing a novel antibiotic impair pathogen colonization

17.10.2016 (Sarah Dräger)
Alexander Zipperer: Human commensals producing a novel antibiotic impair pathogen colonization Nature VO L 5 3 5 511-515 2016

An HIV Pre-Exposure Prophylaxis (PrEP) Demonstration Project and Safety Study for Young MSM

10.10.2016 (Julian Claas)
Sybil Hosek: An HIV Pre-Exposure Prophylaxis (PrEP) Demonstration Project and Safety Study for Young MSM JAIDS Publish Ahead of Print Sept. 13 2016

MERS-CoV outbreak following a single patient exposure in an emergency room in South Korea: an epidemiological outbreak study

03.10.16 (Benedikt Wiggli)
Sun Young Cho et al.: MERS-CoV outbreak following a single patient exposure in an emergency room in South Korea: an epidemiological outbreak study Lancet 388 994-1001 2016

Efficacy of Oral Vancomycin in Preventing Recurrent Clostridium difficile Infection in Patients Treated With Systemic Antimicrobial Agents

26.09.16 (Fabian Franzeck)
Van Hise NW: Efficacy of Oral Vancomycin in Preventing Recurrent Clostridium difficile Infection in Patients Treated With Systemic Antimicrobial Agents Clin Infect Dis 63 651-3 2016

The optimization and validation of the Biotyper MALDI-TOF MS database for the identification of Gram-positive anaerobic cocci

12.09.2016 (Daniel Goldenberger)
Veloo ACM et al.: The optimization and validation of the Biotyper MALDI-TOF MS database for the identification of Gram-positive anaerobic cocci Clin Microbiol Infect 06.016. [Epub ahead of print]. 2016

Very low prevalence of MCR-1/MCR-2 plasmid-mediated colistin  resistance in urinary tract Enterobacteriaceae in Switzerland

05.09.2016 (Andrea Büchler)
Liassine et al.: Very low prevalence of MCR-1/MCR-2 plasmid-mediated colistin  resistance in urinary tract Enterobacteriaceae in Switzerland Int J Infect Dis ijidonline.com 2016

Duration of Antibiotic Treatment in Community-Acquired Pneumonia: A Multicenter Randomized Clinical Trial

29.07.2016 (Michael Osthoff)
Uranga A et al.:Duration of Antibiotic Treatment in Community-Acquired Pneumonia: A Multicenter Randomized Clinical Trial. JAMA Intern Med Epub ahead of print. Jul 25 2016

Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial.

22.08.2016 (Nina Khanna)
Maertens J. et al.: Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial.
Lancet 387(10020) 760-9 2016

Emergence of Acquired HIV-1 Drug Resistance Almost Stopped in Switzerland: A 15year Prospective Cohort Analysis

15.08.2016 (Lisa Brockhaus)
Scherrer A. et al.: Emergence of Acquired HIV-1 Drug Resistance Almost Stopped in Switzerland: A 15year Prospective Cohort Analysis CID 2016:62 1310-1316 2016

Elimination of Routine Contact Precautions for Endemic Methicillin-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococcus: A Retrospective Quasi-Experimental Study

08.08.2016 (Florian Banderet-Uglioni)
Martin E et al.: Elimination of Routine Contact Precautions for Endemic Methicillin-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococcus: A Retrospective Quasi-Experimental Study Infect Control Hosp Epidemiol 8 1-8 2016

Are first-generation cephalosporins obsolete? A retrospective, non-inferiority, cohort study comparing empirical therapy with cefazolin versus ceftriaxone for acute pyelonephritis in hospitalized patients

25.07.2016 (Sarah Dräger)
Athena L. V. Hobbs Are first-generation cephalosporins obsolete? A retrospective, non-inferiority, cohort study comparing empirical therapy with cefazolin versus ceftriaxone for acute pyelonephritis in hospitalized patients JAC 71 1665-1671 2016

Risk factors associated with infant deaths from pertussis: A case control study

18.07.2016 (Alexa Dierig)
Winter K. et al: Risk factors associated with infant deaths from pertussis: A case control study CID 61 1099 - 1106 2015


Adjunctive Dexamethasone in HIV-Associated Cryptococcal Meningitis

11.07.2016 (Richard Kühl)
Beardsley J. et al.: Adjunctive Dexamethasone in HIV-Associated Cryptococcal Meningitis NEJM Feb 11:374(6) 542-54 2016

Switch to oral antibiotics in the treatment of infective endocarditis is not associated with increased risk of mortality in noneseverely ill patients

04.07.2016 (Benedikt Wiggli)
Mzabi A. et al.: Switch to oral antibiotics in the treatment of infective endocarditis is not associated with increased risk of mortality in noneseverely ill patients Clinical Microbiology and Infection Epub ahead of print S1198-743X 2016

Tenofovir to Prevent Hepatitis B Transmission in Mothers with High Viral Load

27.06.2016 (Veronika Bättig)
Pan CQ. et al.: Tenofovir to Prevent Hepatitis B Transmission in Mothers with High Viral Load N Engl J Med 374(24) 2324-34

A Single Dose Zoledronic Acid Infusion Prevents Antiretroviral Therapy-Induced Bone Loss in Treatment-naïve HIV-infected Patients: a Phase IIb Trial

13.06.2016 (Stefan Erb)
Ighovwerha Ofotokun et al.: A Single Dose Zoledronic Acid Infusion Prevents Antiretroviral Therapy-Induced Bone Loss in Treatment-naïve HIV-infected Patients: a Phase IIb Trial Clinical Infectious Diseases Advance Access published May 18, 2016 1-25 2016

A blood RNA signature for tuberculosis disease risk: a prospective cohort study

06.06.2016 (Julian Claas)
Daniel E Zak A blood RNA signature for tuberculosis disease risk: a prospective cohort study The Lancet Published Online 23.03.2016

Optimal Duration of Antibiotic Therapy in Patients With Hematogenous Vertrebral Osteomyelitis at Low Risk and High Risk of Recurrence

30.05.2016 (Elisabeth Wehrle)
Ki-Ho Park et al.: Optimal Duration of Antibiotic Therapy in Patients With Hematogenous Vertrebral Osteomyelitis at Low Risk and High Risk of Recurrence CID 2016:62 1262-1269 2016

Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients:a randomised, controlled, open-label trial

23.05.2016 (Fabian Franzeck)
de Jong E: Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients:a randomised, controlled, open-label trial Lancet Infect Dis - (Published Online: 29 February 2016) 2016

Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interfon-Free Regimens

02.05.2016 (Marcel Stöckle)
Pawlotsky J-M: Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interfon-Free Regimens Gastroenterology 2016

Haemophilus influenzae with Non-Beta-Lactamase-Mediated Beta-Lactam Resistance: Easy To Find but Hard To Categorize

24.04.2016 (Vladimira Hinic)
Skaare D. et al.: Haemophilus influenzae with Non-Beta-Lactamase-Mediated Beta-Lactam Resistance: Easy To Find but Hard To Categorize JCM 53 3589-3595 2015

Randomized Trial of Longer-Term Therapy for Symptoms Attributed to Lyme Disease

18.04.2016 (Hanni Bartels)
Berende A. et al.: Randomized Trial of Longer-Term Therapy for Symptoms Attributed to Lyme Disease NEJM 374 1209-1220 2016

The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)

04.04.2016 (Richard Kühl)
Singer, M and Deutschman, C The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) JAMA 315(8) 801-810 2016

How many samples and how many culture media to diagnose a prosthetic joint infection: a clinical and microbiological prospective multicenter study

21.03.2016 (Nadia Wohlwend)
Bémer P. et al.: How many samples and how many culture media to diagnose a prosthetic joint infection: a clinical and microbiological prospective multicenter study JCM 54 385-391 2016

Posttranscriptional Control of T Cell Effector Function by Aerobic Glycolysis

14.03.2016 (Patrick Gubser)
Chih-Hao Chang Posttranscriptional Control of T Cell Effector Function by Aerobic Glycolysis
Cell 153 1239–1251 2013

Clinical Presentation, Risk Factors, and Outcomes of Hematogenous Prosthetic Joint Infection in Patients with Staphylococcus aureus Bacteremia

07.03.2016 (Benedikt Wiggli)
Tande A. et al.: Clinical Presentation, Risk Factors, and Outcomes of Hematogenous Prosthetic Joint Infection in Patients with Staphylococcus aureus Bacteremia Am J Med 129(2) 221.e11–221.e20 2016

Antibody Levels and Protection After Hepatitis B Vaccine: Results of a 30-Year Follow-up Study and Response to a Booster Dose

22.02.2016 (Julian Claas)
Bruce M. Antibody Levels and Protection After
Hepatitis B Vaccine: Results of a 30-Year Follow-up Study and Response to a Booster Dose
JID J Infect Dis.(2016) doi: 10.1093/infdis/jiv748 First published online: January 21, 2016

Combination of Vancomycin and β-Lactam Therapy for Methicillin-Resistant Staphylococcus aureus Bacteremia: A Pilot Multicenter Randomized Controlled Trial

08.02.2016 (Florian Banderet-Uglioni)
Davis JS et al.: Combination of Vancomycin and β-Lactam Therapy for Methicillin-Resistant Staphylococcus aureus Bacteremia: A Pilot Multicenter Randomized Controlled Trial CID 62 173-180 2014

Interim Guidelines for Pregnant Women During a Zika Virus Outbreak - United States, 2016

01.02.2016 (Christian Theilacker)
Petersen EE et al.: Interim Guidelines for Pregnant Women During a Zika Virus Outbreak - United States, 2016 Morb Mortal Wkly Rep 65 30 - 33 2016

Whole-genome sequencing for analysis of an outbreak of meticillin-resistant Staphylococcus aureus: a descriptive study

25.01.2016 (Dominik Meinel)
Harris S.R.,et al.: Whole-genome sequencing for analysis of an outbreak of meticillin-resistant Staphylococcus aureus: a descriptive study Lancet ID 13 130-136 2013

Colonization and infection with extended-spectrum β-lactamase-producing Enterobacteriaceae in ICU patients: what impact on outcomes and carbapenem exposure?

18.01.2016 (Sarah Tschudin Sutter)
Barbier F. et al.:Colonization and infection with extended-spectrum β-lactamase-producing Enterobacteriaceae in ICU patients: what impact on outcomes and carbapenem exposure?
J Antimicrob Chemother Epub ahead of print 2016

Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection

11.01.2016 (Elisabeth Wehrle)
G.R. Foster et al.: Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection NEJM 373;27 2608-2617 2015